The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: An international, prospective, phase II trial in localized myxoid liposarcoma—A collaborative Spanish (GEIS), Italian (ISG) and French (FSG) group study.
 
Alessandro Gronchi
Honoraria - Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar; SpringWorks Therapeutics
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar
 
Nadia Hindi
Honoraria - Lilly; PharmaMar
Research Funding - Amgen (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Pharmamar; Roche
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Andres Redondo
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche
Research Funding - Eisai (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Roberta Sanfilippo
No Relationships to Disclose
 
Carlo Morosi
No Relationships to Disclose
 
Josefina Cruz Jurado
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Lilly; Novartis; Pfizer; PharmaMar; Roche
Speakers' Bureau - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; PharmaMar; Roche
Travel, Accommodations, Expenses - Novartis; PharmaMar
 
Pablo Luna Fra
No Relationships to Disclose
 
Javier Martinez-Trufero
Consulting or Advisory Role - PharmaMar
Research Funding - Blueprint Medicines (Inst); Lilly (Inst); PharmaMar (Inst)
Expert Testimony - PharmaMar
Travel, Accommodations, Expenses - Amgen; Merck; PharmaMar; PharmaMar
 
Claudia Maria Valverde Morales
Consulting or Advisory Role - Bayer; Eisai; Lilly; Novartis; Pfizer; PharmaMar
Research Funding - Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Novartis; Pfizer; PharmaMar
 
Jesus Romero
No Relationships to Disclose
 
Javier Peinado
No Relationships to Disclose
 
Claudia Sangalli
No Relationships to Disclose
 
Marie Pierre Sunyach
No Relationships to Disclose
 
Cleofe Romagosa
No Relationships to Disclose
 
Dominique Ranchère-Vince
No Relationships to Disclose
 
Antonio Gutierrez
No Relationships to Disclose
 
Paolo De Tos
No Relationships to Disclose
 
Javier Martin Broto
Honoraria - Bayer; Eisai; Lilly; PharmaMar
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar